Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$75.24 USD

75.24
769,478

-0.11 (-0.15%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $75.25 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 32% (170 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

by Zacks Equity Research

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.

Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.

Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.

Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered

by Zacks Equity Research

Inogen (INGN) slashes revenue and net income guidance for 2019.

DaVita (DVA) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

DaVita (DVA) gains from international revenues in Q1.

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

by Zacks Equity Research

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

Urmimala Biswas headshot

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

by Urmimala Biswas

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top

by Zacks Equity Research

Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.

QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid

by Zacks Equity Research

Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

by Zacks Equity Research

Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.

Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.

Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Surmodics (SRDX) consistently gains traction from its core Medical Devices unit, which witnesses a substantial contribution from the SurVeil pact with Abbott.

Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Fresenius Medical (FMS) gains from solid international revenues in Q1.

HMS Holdings' (HMSY) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Top-line growth, higher commercial and state government revenues and expansion in margins aid HMS Holdings (HMSY) in Q1 earnings. However, increase in cost of services remains a woe.

Integer Holdings (ITGR) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Top-line growth and better performance at Medical and Non-Medical segments benefit Integer Holdings' (ITGR) Q1 results. However, contraction in gross margin remains a dampener.

AMN Healthcare (AMN) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Higher revenues and expansion in gross margin find reflection in AMN Healthcare's (AMN) Q1 results. However, weak performance at Nurse and Allied and Locum Tenens segments remain woes.

Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)

by Zacks Equity Research

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q1 earnings gain from Technology & Equipment unit despite international revenues being down.

Insulet (PODD) Beats Earnings and Revenue Estimates in Q1

by Zacks Equity Research

Insulet (PODD) registers year-over-year improvement in revenues on solid uptake of Omnipod system both in the United States and international markets.

Medidata (MDSO) Q1 Earnings Beat Estimates, Margins fall

by Zacks Equity Research

Medidata (MDSO) witnesses year-over-year revenue growth in double-digits across both operating segments in first-quarter 2019.

PRA Health (PRAH) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

PRA Health's (PRAH) Q1 earnings reflect top-line growth, favorable segmental performance and margin expansion.

Globus Medical (GMED) Q1 Earnings Miss Mark, Margins Weak

by Zacks Equity Research

Globus Medical (GMED) management states that the first quarter of a year poses a seasonal challenge to the company's capital equipment, which grossly affects its sales in Q1.